newsfilter
← Latest News
GlobeNewswire·

Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

Real-world, retrospective analysis of Phase 2 patients versus matched controls finds FCR001-treated patients have improved kidney function and fewer cardiometabolic complications than patients on immunosuppression after 5 years In long-term